Background: Cardiac abnormalities are frequent in patients with atherosclerotic renovascular disease (ARVD). The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial studied the effect of percutaneous renal revascularization combined with medical therapy compared with medical therapy alone in 806 patients with ARVD. Methods: This was a pre-specified sub-study of ASTRAL (clinical trials registration, current controlled trials number: ISRCTN59586944), designed to consider the effect of percutaneous renal artery angioplasty and stenting on change in cardiac structure and function, measured using cardiac magnetic resonance (CMR) imaging. Fifty-one patients were recruited from six selected ASTRAL centres. Forty-four completed the study (medical therapy n ¼ 21; revascularization n ¼ 23). Full analysis of CMR was possible in 40 patients (18 medical therapy and 22 revascularization). CMR measurements of left and right ventricular end systolic (LV and RVESV) and diastolic volume (LV and RVEDV), ejection fraction (LVEF) and mass (LVM) were made shortly after recruitment and before revascularization in the interventional group, and again after 12 months. Reporting was performed by CMR analysts blinded to randomization arm. Results: Groups were well matched for mean age (70 versus 72 years), blood pressure (148/71 versus 143/74 mmHg), degree of renal artery stenosis (75 versus 75%) and comorbid conditions. In both randomized groups, improvements in cardiac structural parameters were seen at 12 months, but there were no significant differences between treatment groups. Median left ventricular changes between baseline and 12 months (medical versus revascularization) were LVEDV À1.9 versus À5.8 mL, P ¼ 0.4;
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Background: Cardiac abnormalities are frequent in patients with atherosclerotic renovascular disease (ARVD). The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial studied the effect of percutaneous renal revascularization combined with medical therapy compared with medical therapy alone in 806 patients with ARVD. Methods: This was a pre-specified sub-study of ASTRAL (clinical trials registration, current controlled trials number: ISRCTN59586944), designed to consider the effect of percutaneous renal artery angioplasty and stenting on change in cardiac structure and function, measured using cardiac magnetic resonance (CMR) imaging. Fifty-one patients were recruited from six selected ASTRAL centres. Forty-four completed the study (medical therapy n ¼ 21; revascularization n ¼ 23). Full analysis of CMR was possible in 40 patients (18 medical therapy and 22 revascularization). CMR measurements of left and right ventricular end systolic (LV and RVESV) and diastolic volume (LV and RVEDV), ejection fraction (LVEF) and mass (LVM) were made shortly after recruitment and before revascularization in the interventional group, and again after 12 months. Reporting was performed by CMR analysts blinded to randomization arm. Results: Groups were well matched for mean age (70 versus 72 years), blood pressure (148/71 versus 143/74 mmHg), degree of renal artery stenosis (75 versus 75%) and comorbid conditions. In both randomized groups, improvements in cardiac structural parameters were seen at 12 months, but there were no significant differences between treatment groups. Median left ventricular changes between baseline and 12 months (medical versus revascularization) were LVEDV À1.9 versus À5.8 mL, P ¼ 0.4; LVESV À2.1 versus 0.3 mL, P ¼ 0.7; LVM À5.4 versus À6.3 g, P ¼ 0.8; and LVEF À1.5 versus À0.8%, P ¼ 0.7. Multivariate regression also found that randomized treatment assignment was not associated with degree of change in any of the CMR measurements. Conclusions: In this sub-study of the ASTRAL trial, renal revascularization did not offer additional benefit to cardiac structure or function in unselected patients with ARVD.
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I N T R O D U C T I O N
Patients with atherosclerotic renovascular disease (ARVD) have a high prevalence of cardiac structural and functional abnormalities [1] and they are at high risk of cardiovascular mortality. A cross-sectional echocardiographic study of 79 ARVD patients showed that only 5% had structurally normal hearts, and that although left ventricular ejection fraction (LVEF) (mean 53%) was surprisingly well preserved, left ventricular hypertrophy (LVH) was present in 79% and evidence of diastolic dysfunction in 75% [2] . This burden of structural abnormalities in patients with ARVD is higher than is seen in chronic kidney disease (CKD) [3, 4] or hypertension [5] .
There is evidence that increase in left ventricular mass (LVM) predisposes to development of chronic heart failure (CHF) in CKD of any cause [6] . Heart failure, either flash pulmonary edema (FPE) or CHF, is a well-recognized clinical presentation for ARVD. Although the hearts of patients with FPE 
have not been subject to systematic study, Kane et al. did examine the hearts of ARVD patients being referred for renal revascularization at the Mayo clinic [7] , dividing patients into those with and without clinical heart failure; mean LVM was greater in those with CHF (LVM index 130 6 34 versus 112 6 31 g/m 2 ). Randomized controlled trials (RCTs) comparing the addition of percutaneous renal artery revascularization with optimal medical therapy in ARVD have, at best, shown only minor and inconsistent benefits in blood pressure control [8] [9] [10] . However, case reports have described both reductions in circulating levels of angiotensin II following non-randomized intervention [11] , and improvements in left ventricular structural and functional parameters [11, 12] .
The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial commenced recruitment in 2002 [9] . The aim of this RCT in 806 patients with anatomically significant atherosclerotic Renal Artery Stenosis (RAS) was to determine whether renal revascularization provided additional clinical benefit to medical therapy. The primary outcome measure was renal functional improvement measured using serum creatinine, with secondary outcomes including blood pressure control, renal events, cardiovascular events and death. At the time of initiating recruitment into ASTRAL, there were no RCTs that had examined the effect of renal revascularization upon the hearts of patients with ARVD. This cardiac magnetic resonance (CMR) sub-study of ASTRAL was therefore developed, with the aim of examining the effects of revascularization upon cardiac structure and function within the setting of an RCT.
M A T E R I A L S A N D M E T H O D S

Study design
Full details of the design of ASTRAL have been published previously [9] (clinical trials registration, current controlled trials number: ISRCTN59586944). In brief, this was a multicentre, non-blinded randomized clinical trial comparing rate of change in renal function between patients managed with percutaneous renal artery revascularization in addition to medical therapy against those managed with medical therapy alone. Support was received from the Medical Research Council UK, Kidney Research UK and Medtronic. Ethical approval was granted by the West Midlands Multicentre Research Ethics Committee and the ethics committee relevant to each individual participating study centre. All patients provided written consent. Ethical permission for the cardiac sub-studies was obtained after commencement of the main ASTRAL trial.
Patient selection and randomization
Patients were eligible for inclusion within the main ASTRAL study if they had at least one renal artery with an atherosclerotic stenosis suitable for percutaneous revascularization. Patients were not enrolled if the physician was certain that the patient definitely should or should not undergo renal revascularization. Patients with non-atheromatous disease, those who had undergone a previous revascularization procedure, required surgical revascularization or were considered to have a high probability of requiring revascularization within the next 6 months on clinical grounds, were also excluded. Eligible patients were randomized in a 1:1 ratio to revascularization in addition to standard medical therapy versus medical therapy alone. Randomization was performed using a computerized minimized-randomization procedure with allocation determined following a telephone call to the central trial office.
For this study, all patients due to be randomized between January 2005 and October 2007 at the six UK recruiting centres with CMR capacity that were participating in the sub-study were approached for consent. No further inclusion criteria were applied. The only additional exclusion criterion was the presence of a contra-indication to magnetic resonance imaging (e.g. claustrophobia, implanted metal).
Sample size
At the time of design of this sub-study there were no published data that described change in CMR parameters following revascularization for RAS. One published study of 20 patients with ischaemic CHF suggested that 15 patients per arm would be required to reliably detect a 3% change in left ventricular ejection fraction (LVEF); 12 patients to detect a 10 mL difference in left ventricular end-diastolic volume (LVEDV); and 9 patients to detect a 10 g/m change in left ventricular mass index (LVMI) [13] . The sample size was therefore set at 25 patients in each treatment arm. Allowing for 15% dropout the total recruitment target was 58 patients.
Treatment and follow-up
Medical therapy and renal revascularization procedures were performed in accordance with local guidelines for each participating centre as described previously. As in the main ASTRAL study protocol, patients in the CMR sub-study underwent a repeat assessment at 12 months that included repeat of baseline clinical measurements, creatinine, haemoglobin and review of prescribed medications. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault formula [14] as the study predated widespread application of the MDRD formula. Blood pressure measurements were performed by trained staff using mercury sphygmomanometers after patients had been seated at rest for 5 min, with the elbow supported above the waist and the palm facing upwards. Three readings were taken, with the average of the second and third values recorded.
Cardiac magnetic resonance imaging protocol and analysis
A single unified CMR protocol was agreed between participating centres with imaging performed at baseline and 12 months following randomization. Imaging was performed with a 1.5-Tesla scanner using a phased array chest coil and gated with prospective or retrospective electrocardiographic triggering using fast imaging with steady-state precession. Transverse scout images were used to obtain left ventricular vertical longaxis cine by aligning the LV apex with the centre of the mitral valve at end expiration. From the ventricular long-axis image, a | C a r d i a c s t r u c t u r e a n d f u n c t i o n f o l l o w i n g P T R A S
short-axis view was obtained parallel to the mitral valve halfway between the mitral annulus and LV apex at end expiration. From the short-axis view the horizontal long-axis four chamber plane was aligned passing just above the inferior papillary muscle and through the lower anterior RV free wall where it meets the inferior wall. This was obtained as a cine image at end expiration. A diastolic image at end expiration provided the reference image on which a stack of contiguous short-axis slices were positioned. Breath-hold short-axis cine sections were acquired from the atrio-ventricular ring to the apex, with 6.0-mm section thickness and a 4.0-mm gap and one or two sections per breath hold depending on patient abilities and scanner speed.
All scans were read by a single observer, who was an experienced CMR analyst, blinded to the date and order of the scan, as well as to all clinical information including randomization arm. End-systole was defined visually as the phase with the smallest LV volumes. In selection of the most basal slice for LV analysis, slices were considered to be within the left ventricle if the blood volume was surrounded by 50% or more of ventricular myocardium. The apex was the most apical slice in which myocardium remains visible for analysis. On each end-diastolic frame, endocardial and epicardial borders were manually traced, and an endocardial border was traced on the end systolic frame. Papillary muscles and trabeculations were included with the LV mass while RV trabeculations arising from the interventricular septum were excluded. RV volumes were obtained from true trans-axial cine sections. From these values end-diastolic and end-systolic volumes were calculated as well as LV myocardial mass determined by multiplying myocardial tissue volume by the specific gravity of 1.05.
Outcome measures
Cardiac structure and function were assessed using a variety of measures including LVEDV, left ventricular end-systolic volume (LVESV), LVEF and LVM (and similarly for the right side).
Statistical analysis
Analyses were performed on an intention to treat basis with patients analysed in the treatment group to which they were randomized. For all CMR parameters both mean 6 standard deviation and median (interquartile range) were calculated at baseline and 12 months. Mean differences between treatment groups were compared using Student's t-test with results presented as mean difference [95% confidence interval (CI)]; median differences were compared using Wilcoxon two-sample test. Multivariate regression models were constructed to consider the effects of clinically relevant baseline variables (treatment group, age, presence of diabetes, history of coronary heart disease, systolic blood pressure, diastolic blood pressure, degree of stenosis to most affected kidney, renal function, prescription of beta-blockers and renin angiotensin blockade, baseline ventricular measurement) on change in ventricular parameters at 12 months. All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
R E S U L T S Patients and clinical characteristics
A total of 806 patients were recruited to the main ASTRAL study. Between January 2005 and October 2007, 51 patients were enrolled into the CMR sub-study at the 6 participating sites. Seven patients dropped out due to death (n ¼ 1) or failure to complete 12-month CMR (n ¼ 6), giving a final study population of 44 (21 randomized to medical therapy, 23 to medical therapy plus revascularization). Three of the patients randomized to revascularization failed to undergo the stent insertion procedure; no patient in the medical therapy arm received revascularization. CMR quality was adequate for full analysis in 18 medical therapy and 22 revascularized patients.
Baseline patient characteristics and comorbidities were well matched between treatment groups and were representative of the main study population ( Table 1 ). All patients had a RAS of >50% on pre-randomization angiography (MR, computed tomography or direct angiography) with mean RAS estimated at 75% in the most severely affected artery in each group. Mean serum creatinine in the medical group was 160 (range 74-242) lmol/L, compared with 146 (79-201) lmol/L in the revascularization group; no patients had a baseline creatinine in excess of 300 lmol/L. Height data were only available for a minority of patients, and consequently LVM data were considered without adjustment for patient height. In line with the findings of the main study, no significant difference in change in blood pressure or renal function existed between randomized treatment groups at 12 months.
Cardiac magnetic resonance imaging: left ventricular parameters
At recruitment, all LV structural parameters were similar between the medical and revascularization treatment groups with LVEDV median 130 mL (IQR: 108-146) versus 122 mL (97-146); LVESV 40 mL (3-51) versus 38 mL (29-60); and LVM 116 g (98-134) versus 110 g (101-132) ( Table 2) . Nonsignificant improvements in these structural parameters were observed within both randomized arms between baseline and 12 months with median changes for medical and revascularization groups, respectively, being LVEDV À1.9 mL (95% CI À21 to 4) and À5.8 mL (95% CI À17 to 6); LVESV À2.1 mL (95% CI À5 to 4) and 0.3 mL (95% CI À11 to 5); and LVM À5.4 g (95% CI À12 to 6) and À6.3 g (95% CI À15 to À0.2). Comparisons between randomized groups were made for measured LV values at 12 months and for the relative difference between the two arms for the change from baseline to 12-month values. In both analyses, no significant difference between randomized treatment groups was observed (Table 2) .
At baseline, LVEF was well preserved in both groups: medical therapy 69.5% (IQR 63-73), revascularization 69.2% (IQR 59-72) ( Table 2 ). Within each treatment group, minimal differences in ejection fraction were observed at 12 months. There was no significant difference in the between-group comparison of measured 12-month ejection fraction (Table 2 ) and relative change from baseline ejection fraction (Table 3) . Although this sub-study was designed to assess differences in left-sided parameters, right heart measurements were also obtained ( Table 2) . No difference in right ventricular EDV, ESV or ejection fraction was observed between groups either at baseline or at 12 months.
Association between baseline variables and change in left ventricular parameters at 12 months
Sufficiently complete data were available for 31 patients (15 medical therapy, 16 revascularized) to be included in multivariate regression models. Each model was constructed twice using either serum creatinine or eGFR as one of the co-variates in the model. No difference in results or overall model fit (defined using adjusted R 
Complications of revascularization
Procedural complications were not separately analysed for this sub-study. In the main ASTRAL study, serious complications were observed in 23 of 403 patients randomized to revascularization. This included two deaths occurring within 30 days of intervention.
D I S C U S S I O N
This study has not identified any definitive evidence or even signals of additional benefit of renal artery revascularization on left or right ventricular structure or function in patients with atherosclerotic RAS and significant renal impairment.
This finding is in alignment with results of the Renal Artery Stenosis in Coronary Artery Disease (RASCAD) study [15] , a randomized trial of 84 patients with atherosclerotic RAS identified on screening during non-emergency coronary angiography, and in which the effect of revascularization in addition to medical therapy was considered in relation to change in LVMI over a 12-month period. Although patient age was similar, other For body surface area adjusted measurements, data available for 13 patients at baseline (7 medication, 6 PTRAS) and 17 patients at 12 months (8 medical, 9 PTRAS). SD, standard deviation; PTRAS, percutaneous renal angioplasty and stenting. demographics differed from those described in this ASTRAL sub-study, with patients recruited to RASCAD having a lesser degree of RAS (60%), lower systolic blood pressure (around 132 mmHg) and higher baseline eGFR (approximately 60 mL/min/ 1.73 m 2 ). Nevertheless, RASCAD also found that no additional reduction in LVMI was seen in revascularized patients in comparison with medically managed patients, and that LVMI did decrease in both randomized groups. As these two small randomized trials have not confirmed the findings of case series [12] that suggest a significant association between renal artery revascularization and improved left ventricular structure, the potential of a false negative should be considered. In a 12-month echocardiographic series of 43 patients with varying degrees of RAS, LVM remained stable over the follow-up period [16] . Only eight of these patients underwent revascularization and there was a signal towards reduced LVMI and LVEDV index in this sub-group. However, these measurements were made using transthoracic echocardiography, which is much less accurate than CMR [17] . As this study failed to recruit sufficient patients to satisfy the power calculation, it is possible that a genuine effect was missed. However, if this was the case, then the difference would be small and of limited clinical relevance.
The improvements in structural left ventricular measurements at 12 months seen in both of the randomized arms in this study may reflect appropriate use of pharmacotherapy. Since the first trials of percutaneous revascularization for RAS, the nature of what constitutes optimal medical therapy in renovascular disease has been better defined. Most notably there has been a better appreciation of the importance of the use of RAB and statin therapy [18] [19] [20] . RAB has a role in both preventing progression and inducing regression of LVM, independent of changes in blood pressure, in other populations [21, 22] . Although the effect of medication may have marginalized any potential benefits of revascularization in our study, it was surprising that we found use of RAB at baseline was associated with slight deterioration of LVEDV, LVESV and LVEF at 12 months.
A further question that merits discussion is whether more subtle measures of cardiac structural health should be considered. Contemporary CMR techniques permit assessment of myocardial edema and or fibrosis allowing in-depth interrogation of myocardial pathology, potentially identifying patients at higher risk of cardiac events [23] . Angiotensin II-mediated hypertension has been shown to drive myocardial fibrosis [24, 25] ; it may be that in our ARVD patients chronic overstimulation of the renin-aldosterone-angiotensin system had led to irreversible cardiac structural changes by the time of diagnosis. A developing body of literature suggests that a higher burden of myocardial oedema (a precursor to development of fibrosis [26] ) is associated with an increased likelihood of left ventricular remodelling [27, 28] , and so, theoretically, identification of patients with greater degrees of myocardial oedema may select a group with greater likelihood of benefiting from revascularization. Given the systemic atheromatous burden associated with ARVD, development of cardiac abnormalities will be a multifactorial process driven by pre-existing essential hypertension and/or coronary artery disease as well as RAS. Some of these processes will be unaffected by revascularization. Hence, perhaps only those left ventricular abnormalities that are still progressing and are primarily related to RAS should be expected to improve after revascularization. Speckle track echocardiography can demonstrate more subtle abnormalities in myocardial function, manifest by changes in left ventricular strain patterns, and this is being increasingly investigated in patients with CKD [29] . Although CMR protocols with tagging can replicate this, we only evaluated conventional cardiac parameters in this study.
This study has limitations. Most importantly, the sample size was small and the sample size calculation may have been flawed because it was based on CMR data from a small number of patients with CHF, as few other data were available at the time of designing the study. However, given the similarity in outcome between randomized groups it seems unlikely that a larger sample size would have altered the overall findings in this patient group. It is noteworthy that this was a sub-study of a much larger ARVD population in which no overall benefit from renal artery revascularization was observed. As such it is perhaps unsurprising that no difference in change in cardiac structure or function was identified between groups. The issue of patient selection is also important to consider. The suggested bias towards recruitment of lower risk patients (less likely to benefit from revascularization) into ASTRAL has been widely discussed [30] . In those case series that have described cardiac benefits from revascularization, patients have either had a greater burden of stenosis [12] , or more severe symptoms of heart failure at baseline [11] , than that seen in the ASTRAL population. It is plausible that a study targeting more specific cardiac risk patient groups (e.g. ARVD patients with NYHA III-IV symptoms, or those with very severe hypertension) might demonstrate beneficial cardiac changes accompanying renovascular intervention.
In conclusion, in this study the addition of renal artery revascularization to standard medical therapy did not lead to any further changes in cardiac structure or function than management with medical therapy alone. This finding was in a patient cohort in whom no benefit from revascularization was observed in relation to rate of change in renal function, cardiovascular events or death. Current guidelines recognize that some patients may be more likely to benefit from revascularization, for example patients with acute or CHF or with resistant hypertension [31] with supporting evidence for this in large case series [32] . These may be patient groups in whom improvements in cardiac structure are more likely to follow revascularization. This substudy was inadequately powered to consider effects in specific sub-groups, and patients with acute heart failure were not included in ASTRAL. Future studies that investigate whether cardiac structural and functional changes might accompany renal artery revascularization should address carefully selected patient populations.
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